ArticleCirculation2025
Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells.
Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Induction of Smooth Muscle Differentiation in Fibroblasts by Modulation of Cytoplasmic Actin Ratio.International journal of molecular sciences · 2026Article
- 3D bioprinting of microfluidic systems for cardiac regenerative medicine: from biofabrication to organ-on-a-chip.Journal of biological engineering · 2026Review
- Biomimetic hydrogel design strategies for vascular grafts and vascularized tissue constructs.Frontiers in bioengineering and biotechnology · 2026Review
- Article
- Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis.Journal of translational medicine · 2025Article
- Reprogrammed Smooth Muscle Cells for Vascular Repair: A New Path to Healing Ischemic Tissue.Circulation · 2025Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
backgroundAlthough cell therapy has emerged as a promising approach to promote neovascularization, its effects are mostly limited to capillaries. To generate larger or more stable vessels, layering of mural cells such as smooth muscle cells (SMCs) or pericytes is required. Recently, direct reprogramming approaches have been developed for generating SMCs. However, such reprogrammed SMCs lack genuine features of contractile SMCs, a native SMC phenotype; thus, their therapeutic and vessel-forming potential in vivo was not explored. Therefore, we aimed to directly reprogram human dermal fibroblasts toward contractile SMCs (rSMCs) and investigated their role for generating vascular mural cells in vivo and their therapeutic effects on ischemic disease.
methodsWe applied myocardin and all-
resultsOur novel culture conditions using myocardin and all-
conclusionsA combination of myocardin and all-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.